Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献73篇:

客户使用该产品的13个实验数据:

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NInMXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvOVWZ5PzJiaB?= M4LNVWROW09? NHXDN4FKSzVyPUCuNFAxODdizszN MnTiNVc6PTZyOEC=
K562 NUn5RpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIiwZ|A4OiCq M1zDO2ROW09? NFjibJJKSzVyPUCuNFAyKM7:TR?= Ml62NVc6PTZyOEC=
M07e MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\hOHVjPzJiaB?= MY\EUXNQ NYDsfFZVUUN3ME2wMlAxOTJizszN M3LTOVE4QTV4MEiw
ALL3 MmfoR5l1d3SxeHnjJGF{e2G7 NXHCPIlmOC5zzszN NXXXbYhiPzJiaB?= MkH1SG1UVw>? NHrvelRKSzVyPUCuNFAxPCEQvF2= M1;6NlE6QDh7NUSw
CML Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnPdItXOjBibXnu NVn6dYdSTE2VTx?= NFLLUHVKSzVyPUCuNFAyKM7:TR?= MoPsNVkzOTlyMU[=
BA/F3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO4VVdoPzJiaB?= MYfEUXNQ NInXe2VKSzVyPU[uOVg6KM7:TR?= NVPTTph6OjNyOEi2OFQ>
BA/F3 M3XzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:2O|IhcA>? Ml\RSG1UVw>? MmPRTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MUKyN|A5QDZ2NB?=
BA/F3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXLcJZVPzJiaB?= M1fTbmROW09? NIniRnFKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MlPWNlMxQDh4NES=
BA/F3 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jvNFczKGh? MYnEUXNQ MmPHTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP M1qzS|I{ODh6NkS0
BA/F3 M4TteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp NXLxe3g5TE2VTx?= M1rwTWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP NGX5cJgzOzNyMUewNy=>
BA/F3 M2ru[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\2ZVczKGh? NVTpOIw1TE2VTx?= MoXGTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? NVzJfm5EOjN|MEG3NFM>
BA/F3 NV76S2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp M2nLNWROW09? Mli4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? MYmyN|MxOTdyMx?=
BA/F3 NH3VXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPaZlF[PzJiaB?= NEm0eIRFVVOR MoLSTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MVuyN|MxOTdyMx?=
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO3O|IhcA>? M{DzemROW09? NFPEZpVKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MUOyN|MxOTdyMx?=
BA/F3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjJO|IhcA>? M2fSb2ROW09? MWLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> MmTuNlM{ODF5MEO=
BA/F3 NF;QcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfEO|IhcA>? MmDrSG1UVw>? MWjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NYT4co81OjN|MEG3NFM>
BA/F3 M2PBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq3NkBp MmfiSG1UVw>? MmfFTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> NEPkbI0zOzNyMUewNy=>
BA/F3 M4HLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp NYDqZ5dVTE2VTx?= MWXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? NUDweZp4OjN|MEG3NFM>
T cell MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknLO|IhcA>? NULqVYNITE2VTx?= M4nQfmlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MoO4NVcyPTR3MUK=
WiDr Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUUno4OiCq MV3EUXNQ MnjCTWM2OD1yLkC1NkDPxE1? NVTkXII6OTV4MUW1NVI>
PC3 M{HnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fScFczKGh? NVPudmxRTE2VTx?= Mn;lTWM2OD1yLkCwPVQh|ryP M2fNPFE2PjF3NUGy
MDA-MB-231 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYdW9pPzJiaB?= MnLoSG1UVw>? M1TMXGlEPTB;MD6wNVIh|ryP NYPCfpN[OTV4MUW1NVI>
Hs578T MonRR5l1d3SxeHnjJGF{e2G7 NV\CVlJmPzJiaB?= MmnZSG1UVw>? MVTHTVUxRTBwMEOg{txO NV7XOHVmOjRyMUWzNlc>
HMEC NHi3U5BEgXSxdH;4bYMhSXO|YYm= MkjFO|IhcA>? NEfTTGZFVVOR MVzHTVUxRTFwODFOwG0> NVPlZlZDOjRyMUWzNlc>
DU145 M13VeWN6fG:2b4jpZ{BCe3OjeR?= NHjiO3c4OiCq MVjEUXNQ NVv3b293T0l3ME2wMlE3KM7:TR?= Mln4NlQxOTV|Mke=
U251 NF61fWFEgXSxdH;4bYMhSXO|YYm= MmD6O|IhcA>? NVzMblVvTE2VTx?= NXfHbIN3T0l3ME2yMlgyKM7:TR?= NYLZPWpCOjRyMUWzNlc>
NCI60 MlvrR5l1d3SxeHnjJGF{e2G7 M13BPFczKGh? NUPhNYNOTE2VTx?= MWLHTVUxRTVwNzFOwG0> MmLpNlQxOTV|Mke=
MALME-3M NVnwVJByS3m2b4TvfIlkKEG|c3H5 M{fpTFczKGh? NE\Tb5VFVVOR NGHLOVdIUTVyPU[uOlEh|ryP M{Pmb|I1ODF3M{K3
KM12 M170RWN6fG:2b4jpZ{BCe3OjeR?= NWfmZVFNPzJiaB?= M1XqRWROW09? MULHTVUxRTdwNESg{txO NVvOfoU2OjRyMUWzNlc>
SW620 NFnaToVEgXSxdH;4bYMhSXO|YYm= NFfDUYg4OiCq M4PtfmROW09? MnjFS2k2OD16LkSzJO69VQ>? Mn;NNlQxOTV|Mke=
RXF 393NL NUfEeXlNS3m2b4TvfIlkKEG|c3H5 NVvjSlFuPCCmYYnz NVW1cWtPTE2VTx?= MUjJR|UxRTBwMEKxO{DPxE1? NEfmV2ozOzJ3M{C3OC=>
LXFA 983L M3rNcGN6fG:2b4jpZ{BCe3OjeR?= NHO2WXc1KGSjeYO= MYrEUXNQ NXG5XZBPUUN3ME2wMlA2PjVizszN NHLqXJozOzJ3M{C3OC=>
PRXF DU145 NHjWS5dEgXSxdH;4bYMhSXO|YYm= M2HLWlQh\GG7cx?= NFuyb5ZFVVOR MVzJR|UxRTBwME[yN{DPxE1? MV[yN|I2OzB5NB?=
PAXF 1657L NVfwe3ZbS3m2b4TvfIlkKEG|c3H5 NHu3ZXk1KGSjeYO= MW\EUXNQ NXuxNGpTUUN3ME2wMlEzOSEQvF2= Ml\UNlMzPTNyN{S=
CXF 1103L NHnFPZREgXSxdH;4bYMhSXO|YYm= NX;NVWZwPCCmYYnz NW[ycWdyTE2VTx?= NXPD[YpVUUN3ME20MlM3KM7:TR?= MnvuNlMzPTNyN{S=
GXF251L M{HHbWN6fG:2b4jpZ{BCe3OjeR?= MWC0JIRigXN? MoXlSG1UVw>? MVXJR|UxRTJwMkWg{txO NV3vcGxxOjN{NUOwO|Q>
NCI-H23 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjqfY44OiCq MVjEUXNQ MonWTWM2OD1{LkK3JO69VQ>? MmjCNlM2OjFyMkC=
HCT116 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS3NkBp Mn;4SG1UVw>? NUG5XZkyUUN3ME2yMlMh|ryP MXuyN|UzOTB{MB?=
MCF7 NGnWSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG3NkBp NFPMeWxFVVOR MWPJR|UxRTJwNUeg{txO MlXVNlM2OjFyMkC=
NCI-H460 M1TJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr6NGNFPzJiaB?= NWLGbJJvTE2VTx?= NFHUUmdKSzVyPUiuPVkh|ryP M171VlI{PTJzMEKw
DLD1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXVO|IhcA>? NEOxcINFVVOR MkfpTWM2OD12Lk[g{txO MlvmNlM2Pjd7NkC=
NCI-H661 NHq3WlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;JTFczKGh? MmLmSG1UVw>? NVjSfnZSUUN3ME23Mlgh|ryP NXrlcmtqOjN3Nke5OlA>
A549 M{XrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXe3NkBp NUfMbnRWTE2VTx?= NHrzdoNKSzVyPUiuNkDPxE1? M4rtRlI{PTZ5OU[w
U937 NWDhUXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlezO|IhcA>? NEHPXFRFVVOR MkPBTWM2OD1zMj6yJO69VQ>? NV;pPYx2OjN3Nke5OlA>
HEK293 NXXIfnJGTnWwY4Tpc44hSXO|YYm= NWTPOXFROTEEoN88US=> NXvkSYF5TE2VTx?= MWLJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= M3Lm[lIzPzdyNkGw
HUVEC NHT5S|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGwMlE2yqEQvF2= NGey[mg4OiCq MmLVSG1UVw>? MVLJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= M1X3WFIzQDV|OUmz
HUVEC MnXHSpVv[3Srb36gRZN{[Xl? M{HUWVE2yqEQvF2= MnTrO|IhcA>? MoDhSG1UVw>? NIHZbVBKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? M17qV|IzQDV|OUmz
Plasmodium falciparum NX;Ie5BSTnWwY4Tpc44hSXO|YYm= M161V|ExyqEQvF2= MXSxOUBucW5? M2rIe2ROW09? NWPVUJEyUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NI[0VpQzPDV3MEOzNC=>
PC3 NVPzeGV3TnWwY4Tpc44hSXO|YYm= NUfvWopIOC5zIN88US=> MVe1JIg> NUjVXY5PTE2VTx?= NWS2N4I6UW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N NI\3NY4yQTR4Mkm3OS=>
DU145 NIm5TY5HfW6ldHnvckBCe3OjeR?= Mmi5NE4yKM7:TR?= NXWzeXl5PSCq MXfEUXNQ MV3Jcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MWSxPVQ3Ojl5NR?=
PC3 MkjYT4lv[XOnIFHzd4F6 MkeyNE4yKM7:TR?= MoqwOUBp NUXWcItiTE2VTx?= NVvpTmFKUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MlTLNVk1PjJ7N{W=
DU145 NIXZXGZMcW6jc3WgRZN{[Xl? MVWwMlEh|ryP M2LvSlUhcA>? NVHhT|RUTE2VTx?= NYHCSod3UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O M1foZ|E6PDZ{OUe1
PC3 M3jn[WtqdmG|ZTDBd5NigQ>? NXrBUJpQOC5zIN88US=> M4X3OlUhcA>? M1TYXmROW09? MVrJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M1;Eb|E6PDZ{OUe1
DU145 M{PCRmtqdmG|ZTDBd5NigQ>? NIPZTFgxNjFizszN MVq1JIg> MVzEUXNQ NEnyPHBKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NF\mWncyQTR4Mkm3OS=>
Huh7 MkHNRY51cX[rcnHsJGF{e2G7 MYqyMlUh|ryP MYq0JIRigXN? M1LIbmROW09? NIjVe|lKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NFH5XpAyPzN4ME[3Oi=>
C6/36 MmfBRY51cX[rcnHsJGF{e2G7 MX:yMlUh|ryP MWm0JIRigXN? Mlf5SG1UVw>? M{XjVmlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NGm2PVAyPzN4ME[3Oi=>
U937 NXSyR4pMTnWwY4Tpc44hSXO|YYm= NHrGUYQyKM7:TR?= NWW4eXI3OSCq NED6elFFVVOR NVvKU5FkWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NW\SfGhOOTd4OESwPVk>
U937 NHzqNFlHfW6ldHnvckBCe3OjeR?= Ml;zNUDPxE1? NFLSWpgyKGh? MYjEUXNQ MoHQVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> M{jQcFE4Pjh2MEm5
murine mast cell M3fRPWZ2dmO2aX;uJGF{e2G7 M2\XPVEh|ryP MViyOEBp MUjEUXNQ M1;MeGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP Mn7TNVc3QDRyOUm=
BV-173 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzEWmcxUUN3ME2wMlAxODByMEGwPUDPxE1? MkXDV2FPT0WU
K-562 NETtZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMECwNFAxOjZ4IN88US=> NFzLcotUSU6JRWK=
BL-70 M1X0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mw[mlEPTB;MD6wNFAxODB6MkKg{txO Mk[xV2FPT0WU
EM-2 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonjTWM2OD1yLkCwNFAxOTB6IN88US=> M2\P[3NCVkeHUh?=
LAMA-84 NFXGNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zRN2lEPTB;MD6wNFAxODN{MTFOwG0> NHrrOWRUSU6JRWK=
MEG-01 NFLTOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnKTWM2OD1yLkCwNFAxQThizszN MUPTRW5ITVJ?
EoL-1-cell MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:2VoVyUUN3ME2wMlAxODBzM{Gg{txO NUfHXm02W0GQR1XS
CTV-1 NX3JV|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnmWZAxUUN3ME2wMlAxODB2MESg{txO MlLCV2FPT0WU
TE-15 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD1yLkCwOVg6KM7:TR?= NEG2d|RUSU6JRWK=
NOS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEC2NVMh|ryP NVnMd2g1W0GQR1XS
D-336MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nJPWlEPTB;MD6wNFY{KM7:TR?= M3rkR3NCVkeHUh?=
LB1047-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr5TWM2OD1yLkCwPVg6KM7:TR?= MkfjV2FPT0WU
LB996-RCC M1Ty[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEC5PVEh|ryP M4LkOHNCVkeHUh?=
SW982 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3j[XRKSzVyPUCuNFEyOTVizszN MkTPV2FPT0WU
TK10 NETFeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjyS|RKSzVyPUCuNFEyPzRizszN M1nT[XNCVkeHUh?=
A704 NGT5TnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j1V2lEPTB;MD6wNVQ6OSEQvF2= M{nGOXNCVkeHUh?=
TE-8 NIPHVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7abmdKSzVyPUCuNFE2PzZizszN NFf0dGlUSU6JRWK=
DOHH-2 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{juZ2lEPTB;MD6wNVcyQSEQvF2= M3PjPHNCVkeHUh?=
HOP-62 NF;RWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13tNmlEPTB;MD6wNVg{PCEQvF2= MWjTRW5ITVJ?
TE-12 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEG4OlEh|ryP MXvTRW5ITVJ?
KGN Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEG5OFIh|ryP MmL3V2FPT0WU
NCI-H1648 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEKwNVEh|ryP M1f0SXNCVkeHUh?=
OS-RC-2 M17SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEKwN{DPxE1? M4j4WXNCVkeHUh?=
GB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnrb3VWUUN3ME2wMlAzOTV5IN88US=> NF;MXnBUSU6JRWK=
RXF393 NWLBb4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLrTWM2OD1yLkCyN|U4KM7:TR?= M3TqUXNCVkeHUh?=
LC-2-ad M1vHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;jTWM2OD1yLkCyOVg3KM7:TR?= M{LoRXNCVkeHUh?=
KS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTpSWNKSzVyPUCuNFI4OyEQvF2= MV7TRW5ITVJ?
ETK-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnCd2JZUUN3ME2wMlAzQDN{IN88US=> MW\TRW5ITVJ?
SW954 NFPSW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X3ZmlEPTB;MD6wNlkzPyEQvF2= MUjTRW5ITVJ?
Becker MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq3TWM2OD1yLkCzNFA{KM7:TR?= MWXTRW5ITVJ?
MZ1-PC NHXUTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEOxNVkh|ryP NEXGVIJUSU6JRWK=
ES6 NXfNZnlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\YV4ptUUN3ME2wMlA{OTl|IN88US=> M2\UPXNCVkeHUh?=
KURAMOCHI MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX20Zm06UUN3ME2wMlA{PDh5IN88US=> Mlf0V2FPT0WU
CGTH-W-1 MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jvU2lEPTB;MD6wN|U1QCEQvF2= NXzmdWl7W0GQR1XS
VA-ES-BJ MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQOVVYUUN3ME2wMlA{QTB{IN88US=> MVPTRW5ITVJ?
LXF-289 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD1yLkCzPVU3KM7:TR?= NWLaN45xW0GQR1XS
MPP-89 M1fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HlR2lEPTB;MD6wOFA1QSEQvF2= NF3OUFZUSU6JRWK=
SW872 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zT[2lEPTB;MD6wOFE3OSEQvF2= MnyzV2FPT0WU
SNB75 M{\0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i2XmlEPTB;MD6wOFQ{PSEQvF2= Mkj1V2FPT0WU
PSN1 NHLVe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPXVGpkUUN3ME2wMlA1PDd2IN88US=> NX;ncplxW0GQR1XS
LB831-BLC NYK1XJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S1eGlEPTB;MD6wOFYxQSEQvF2= NWHpUFRuW0GQR1XS
MFH-ino MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlThTWM2OD1yLkC0O|I1KM7:TR?= MVPTRW5ITVJ?
TGBC24TKB MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMES3OlEh|ryP NEfJSZJUSU6JRWK=
A388 M135U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOzPFZpUUN3ME2wMlA2ODl3IN88US=> MlTPV2FPT0WU
BB30-HNC NVz2ZnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXmOGZKSzVyPUCuNFU1OzdizszN NIDBfG9USU6JRWK=
GI-ME-N NGmzOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjnVY97UUN3ME2wMlA3OTF6IN88US=> M3nMVnNCVkeHUh?=
TGBC1TKB M1HJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\scoF{UUN3ME2wMlA3OTZ2IN88US=> NIOzXWtUSU6JRWK=
TE-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjp[5pKSzVyPUCuNFY{PTdizszN NV3wTZJuW0GQR1XS
A498 M1naZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XJOGlEPTB;MD6wO|I5PCEQvF2= M{\iN3NCVkeHUh?=
TE-11 NFnHOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7jS|NTUUN3ME2wMlA4QDV6IN88US=> MnvPV2FPT0WU
BB65-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;PcpZKSzVyPUCuNFgzOjdizszN NVj1dnFlW0GQR1XS
C2BBe1 NITsd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e5VGlEPTB;MD6wPFMxQCEQvF2= MYPTRW5ITVJ?
NCI-H747 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEizOlIh|ryP MWLTRW5ITVJ?
IST-MES1 NELQXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjDT|NKSzVyPUCuNFg2PTJizszN NX:0WmtSW0GQR1XS
KALS-1 M36xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHBSJlzUUN3ME2wMlA6PDlizszN NHrRRoVUSU6JRWK=
GCIY MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPGTWM2OD1yLkC5OlU3KM7:TR?= NIj6S4VUSU6JRWK=
RL95-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfmTWM2OD1yLkGwN|gh|ryP M1zMZXNCVkeHUh?=
TE-1 NFjkS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMUC1OEDPxE1? MmjEV2FPT0WU
NCI-H1355 NYXhUI0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XTc2lEPTB;MD6xNVAzQCEQvF2= NVz4NpgxW0GQR1XS
SW962 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMUGyPVIh|ryP MnT6V2FPT0WU
KLE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMUGzNVch|ryP NFT4PVNUSU6JRWK=
MC116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\STWM2OD1yLkGxOFEh|ryP NHG2cXFUSU6JRWK=
NMC-G1 MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFNppKSzVyPUCuNVE3ODZizszN M{PCWnNCVkeHUh?=
KU812 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknnTWM2OD1yLkGxPFg{KM7:TR?= M3z0[XNCVkeHUh?=
COLO-829 NEHaWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn1dJhbUUN3ME2wMlEzOjF|IN88US=> MUDTRW5ITVJ?
NTERA-S-cl-D1 M1Lre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD1yLkGyNlg{KM7:TR?= MXfTRW5ITVJ?
IST-MEL1 NF\ISoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMUO0OUDPxE1? MnrJV2FPT0WU
MLMA M4\3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jSPGlEPTB;MD6xOFA{OiEQvF2= M2HkdHNCVkeHUh?=
LS-123 M1XDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrmSGNKSzVyPUCuNVQxPjRizszN NYHSNlZvW0GQR1XS
LB2518-MEL NH\RUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\YZ2RmUUN3ME2wMlE1OTZ{IN88US=> NWjvR|NRW0GQR1XS
NB69 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i1SGlEPTB;MD6xOFQ{PiEQvF2= NUXzUYFlW0GQR1XS
8-MG-BA MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Ke4pXUUN3ME2wMlE2PDV6IN88US=> MYnTRW5ITVJ?
K5 M3LDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLxTWM2OD1yLkG2OFg6KM7:TR?= M4qxUnNCVkeHUh?=
KINGS-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme1TWM2OD1yLkG2OlY3KM7:TR?= M2DSbXNCVkeHUh?=
SF268 M3OwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUe0NFQh|ryP MkDYV2FPT0WU
PF-382 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\xOGlEPTB;MD6xO|Y4QCEQvF2= Ml3LV2FPT0WU
SH-4 M{nrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PWeGlEPTB;MD6xPFQyOyEQvF2= NHXMOGdUSU6JRWK=
NALM-6 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfNbpZJUUN3ME2wMlE6Ojl3IN88US=> NEPIOHJUSU6JRWK=
CP66-MEL M2Pp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUm1N|Eh|ryP MoTkV2FPT0WU
697 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj0TWM2OD1yLkG5PVg4KM7:TR?= M3Xx[HNCVkeHUh?=
CP67-MEL NUnZeZBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFU5N2UUN3ME2wMlIxPDh6IN88US=> NXHv[WFUW0GQR1XS
DSH1 NUHEUWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nxeGlEPTB;MD6yOFAxOSEQvF2= MYLTRW5ITVJ?
HCE-4 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMk[0N|kh|ryP NGT6OIZUSU6JRWK=
MZ2-MEL Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO2Z5dKSzVyPUCuNlg2OzdizszN MVLTRW5ITVJ?
BL-41 M37C[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK4TnZKSzVyPUCuNlkyOjNizszN NVTHSG9ZW0GQR1XS
HUTU-80 NXv4eG17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ybmlEPTB;MD6zNVQzKM7:TR?= NV65OZVNW0GQR1XS
LOXIMVI NIrVfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfO[XBVUUN3ME2wMlMyPTB|IN88US=> MmLFV2FPT0WU
no-10 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTDTWM2OD1yLkOxPVMyKM7:TR?= M4PLenNCVkeHUh?=
KARPAS-422 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDYTWM2OD1yLkOzPVk4KM7:TR?= MUXTRW5ITVJ?
SW684 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX1XZFKSzVyPUCuN|Q6QCEQvF2= NG\KfldUSU6JRWK=
SF126 NEXa[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vJOmlEPTB;MD6zOVQyKM7:TR?= MkP2V2FPT0WU
D-263MG NY\0e2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwM{[yNlQh|ryP NFPwUJlUSU6JRWK=
OVCAR-4 NWDWXHdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHOem5pUUN3ME2wMlM4PDN|IN88US=> NHO5S49USU6JRWK=
BB49-HNC MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMNldIUUN3ME2wMlM5PTl7IN88US=> M4KwSnNCVkeHUh?=
ONS-76 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zabWlEPTB;MD60Nlk2OSEQvF2= NWnSVGRWW0GQR1XS
MZ7-mel NXPjeYlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNEe5NVEh|ryP NXz6VphTW0GQR1XS
RCC10RGB NF7vO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiwTWM2OD1yLkS5NVEh|ryP NET6NJBUSU6JRWK=
BOKU NF;nVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNEmxN|Mh|ryP NVj6VY1bW0GQR1XS
no-11 NYHUUYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:5ZWlEPTB;MD61NFIzQCEQvF2= NIr5ToZUSU6JRWK=
IST-SL2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\zU2NKSzVyPUCuOVA{ODJizszN MUDTRW5ITVJ?
RKO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKzZlJwUUN3ME2wMlUzQTZ4IN88US=> M{m4fXNCVkeHUh?=
HT-144 NHW5VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfhTWM2OD1yLkWzOlA6KM7:TR?= NHLOV2tUSU6JRWK=
NCI-H446 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwNkK3OkDPxE1? MWfTRW5ITVJ?
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGOGlEPTB;MD63NFYzQSEQvF2= NGT1cpNUSU6JRWK=
MHH-PREB-1 NUnHZWQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS1W2lxUUN3ME2wMlc1PDZ7IN88US=> M3;GSHNCVkeHUh?=
EW-16 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwN{[xO|gh|ryP NWjhR2dXW0GQR1XS
EW-24 M1nGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn3c|R6UUN3ME2wMlc5OTZ3IN88US=> MonuV2FPT0WU
LB373-MEL-D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLSWh1UUN3ME2wMlgzPTB6IN88US=> NYLHSpdOW0GQR1XS
TE-9 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwOEe1N|Ih|ryP Mn3NV2FPT0WU
A3-KAW Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1yLkm4OFUzKM7:TR?= MY\TRW5ITVJ?
A101D MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTRbJVKSzVyPUGuNFMxPDNizszN MljvV2FPT0WU
OCUB-M NXS2[mZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMES0NVIh|ryP MXjTRW5ITVJ?
ES4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\kPJpvUUN3ME2xMlA2OTR3IN88US=> NFrBeJNUSU6JRWK=
TE-6 NHTWV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP4TWM2OD1zLkKxNlI3KM7:TR?= M3jHcHNCVkeHUh?=
D-502MG NX3LfpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwMkOzO|Yh|ryP M2[5fnNCVkeHUh?=
KNS-42 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPPT2FKSzVyPUGuNlQ1OTJizszN MULTRW5ITVJ?
SNU-C2B M2n2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zoOWlEPTB;MT6zNFU5QSEQvF2= M17hV3NCVkeHUh?=
NCI-H1838 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvySHdKSzVyPUGuN|A4OzNizszN MnvrV2FPT0WU
NKM-1 NILrcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrLOJBIUUN3ME2xMlMxQDV7IN88US=> MWTTRW5ITVJ?
GI-1 NInzPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlftTWM2OD1zLkO2NlIh|ryP M1mzfXNCVkeHUh?=
NB5 NYHWc2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xN21KSzVyPUGuN|k5OjdizszN MoT3V2FPT0WU
CAS-1 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3DdoVXUUN3ME2xMlQxQTl{IN88US=> MXXTRW5ITVJ?
HCE-T MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDzXo5KSzVyPUGuOVY4OTRizszN MnrjV2FPT0WU
SBC-1 NHPrbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3TWM2OD1zLkW3PVg1KM7:TR?= Mnz2V2FPT0WU
JiyoyeP-2003 NVnhVpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjZWXhKUUN3ME2xMlc{PDZ4IN88US=> NH;YbmFUSU6JRWK=
TE-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwN{mxN|kh|ryP M2niN3NCVkeHUh?=
CAN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13QUmlEPTB;MT64NlI2OiEQvF2= MUjTRW5ITVJ?
SK-UT-1 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjwTWM2OD1{LkG2Olk{KM7:TR?= MVLTRW5ITVJ?
JVM-2 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1{LkO2Nlg1KM7:TR?= M2KwfnNCVkeHUh?=
LB771-HNC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfpTWM2OD1{LkW3OVUyKM7:TR?= NYTqcGVFW0GQR1XS
NCCIT MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwOE[2NVYh|ryP NVK3SGI6W0GQR1XS
NCI-H2126 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvKXnh{UUN3ME2yMlg4PTV{IN88US=> Mn\4V2FPT0WU
Calu-6 NFztW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEZotZUUN3ME2zMlA2PzRzIN88US=> NFX1OmRUSU6JRWK=
SK-LMS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLhTmdqUUN3ME2zMlEyQDh4IN88US=> MXTTRW5ITVJ?
ARH-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNwNE[5NVUh|ryP MlHSV2FPT0WU
NB17 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHmRldZUUN3ME2zMlY{QDR5IN88US=> NF\iT2JUSU6JRWK=
A253 NFr4UZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LQRWlEPTB;Mz63N|I1PiEQvF2= MXLTRW5ITVJ?
OPM-2 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRwMke2PFUh|ryP MmryV2FPT0WU
MV-4-11 NX70d4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrqZYNKSzVyPUSuN|Y1PTRizszN NYOxeoNUW0GQR1XS
SR NEf2Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS0TWM2OD12LkS5PVU1KM7:TR?= MWXTRW5ITVJ?
KG-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrPTWM2OD12Lk[wPFQ2KM7:TR?= M1fMbnNCVkeHUh?=
OCI-AML2 NXTlVWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHaTWM2OD13Lki2NVU1KM7:TR?= M4DzWXNCVkeHUh?=
D-247MG NEjXTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrwTWM2OD14LkGyOVE6KM7:TR?= MVnTRW5ITVJ?
DJM-1 NGSzcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXvXY9KSzVyPU[uOFg2PThizszN MmT1V2FPT0WU
RPMI-6666 NXLpSGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vNWGlEPTB;Nz6yO|A3PyEQvF2= MYLTRW5ITVJ?
KARPAS-45 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwNUG2O|Eh|ryP NGDWdFFUSU6JRWK=
LP-1 NILZeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPycmE1UUN3ME23MlU1Pzh{IN88US=> Mn35V2FPT0WU
RS4-11 NXPmSIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDyOnhmUUN3ME23MlY2Pzh5IN88US=> M2nHOXNCVkeHUh?=
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRThwMkG2OVIh|ryP NFXoT4xUSU6JRWK=
MONO-MAC-6 NV[0SldRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jXOWlEPTB;OD6yO|A3PiEQvF2= MU\TRW5ITVJ?
NCI-SNU-16 M2TTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjtTmo1UUN3ME24MlU3OTJ6IN88US=> M4jLXHNCVkeHUh?=
SJSA-1 NX\WOmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm5eppjUUN3ME24MlczQDB3IN88US=> M3LHTXNCVkeHUh?=
MMAC-SF MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITXWYtKSzVyPUiuO|k{ODdizszN NWPpbVRrW0GQR1XS
SK-NEP-1 NHr4PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliwTWM2OD16Lki5NVU2KM7:TR?= MYTTRW5ITVJ?
J-RT3-T3-5 NYjkcFhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELOUXFKSzVyPUiuPVY2OjlizszN MlHqV2FPT0WU
SKM-1 NYDGPJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPNTWM2OD17LkCxO|M1KM7:TR?= NX7HfHFlW0GQR1XS
LB2241-RCC NEnyeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnoOmppUUN3ME25MlAzODF{IN88US=> NHrvR|hUSU6JRWK=
SIG-M5 M17LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXJZ5JKSzVyPUmuNFI1QTNizszN MULTRW5ITVJ?
EVSA-T MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\HRWlEPTB;OT6yO|c6OyEQvF2= Ml7UV2FPT0WU
GT3TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD17LkO1OVQ3KM7:TR?= MXzTRW5ITVJ?
NB6 M{m1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\sWHRjUUN3ME25MlkzOjV7IN88US=> MX\TRW5ITVJ?
EHEB NX3xWJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf2TWM2OD1zMD6wOlU3KM7:TR?= M{DmcnNCVkeHUh?=
HEL M1jLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFyLkS3O|Yh|ryP MXHTRW5ITVJ?
ALL-PO NEOySnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzlUlNKSzVyPUGwMlc6OzhizszN NF3PTZhUSU6JRWK=
TGW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnOTWM2OD1zMT6yPFI5KM7:TR?= NIi1dldUSU6JRWK=
BC-3 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF{LkGxN|gh|ryP NWHyWo1vW0GQR1XS
IA-LM NVfheIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPXXW1iUUN3ME2xNk41PDR3IN88US=> NETzZmFUSU6JRWK=
UACC-257 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{LkmxPVgh|ryP M{izZXNCVkeHUh?=
KP-N-YS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P0NWlEPTB;MUKuPVI5OyEQvF2= MYDTRW5ITVJ?
Raji Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHqTWM2OD1zMz63OFk4KM7:TR?= MmrYV2FPT0WU
SF539 NHvuTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzITWM2OD1zMz64OVU4KM7:TR?= Mm\DV2FPT0WU
DMS-153 NWjwRlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF2LkCwNlgh|ryP NYfldW9IW0GQR1XS
L-540 NFXpdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF3LkC2O|Ih|ryP NGfoPIJUSU6JRWK=
MN-60 NWLRSGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF3LkG5O|kh|ryP MlzLV2FPT0WU
RPMI-8866 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3WdXNkUUN3ME2xO{41PDV2IN88US=> NWHkOY1xW0GQR1XS
NCI-H510A M{\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF7LkO5O|Mh|ryP NXriNmxFW0GQR1XS
NB13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M376SmlEPTB;MUmuOFg4PyEQvF2= NHTtdlJUSU6JRWK=
HAL-01 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTye4tKSzVyPUG5Mlc2PDNizszN MknTV2FPT0WU
NCI-H720 NHf2VmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jHNWlEPTB;MkCuNlc{OyEQvF2= NFz4bZhUSU6JRWK=
REH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\DWm5KSzVyPUKwMlY{PTdizszN MYjTRW5ITVJ?
KNS-81-FD MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ|LkG0OkDPxE1? NVPJ[oZyW0GQR1XS
HC-1 M3;4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLjTWM2OD1{ND61OVUyKM7:TR?= M37JUnNCVkeHUh?=
NCI-H2141 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\VV3JSUUN3ME2yOE44PzV2IN88US=> NHLtWXdUSU6JRWK=
MOLT-4 NIDk[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTpOo8xUUN3ME2yOk43PzV|IN88US=> NXTh[oVMW0GQR1XS
OMC-1 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\hWmlEPTB;MkeuNVQzOiEQvF2= MkDwV2FPT0WU
LC-1F NFvMdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rsNWlEPTB;MkeuN|I1PSEQvF2= NXnHT2hZW0GQR1XS
NCI-H1304 NFr2OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D0XGlEPTB;MkiuNVYzQCEQvF2= MW\TRW5ITVJ?
BC-1 NGrmRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ6Lk[1NUDPxE1? NF;CO5dUSU6JRWK=
NCI-H64 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;uSWlEPTB;MkmuOlI2OyEQvF2= NI\3e3lUSU6JRWK=
MOLT-16 NEH0OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrBTpZPUUN3ME2yPU43Ojl{IN88US=> MWnTRW5ITVJ?
U-87-MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNyLke2OkDPxE1? M33NU3NCVkeHUh?=
GAK NXjFeWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNzLkK2PFYh|ryP MYfTRW5ITVJ?
ES8 NHPBPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLCTWM2OD1|Mj6xNlUzKM7:TR?= MXzTRW5ITVJ?
HCC1599 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn6U3ZKSzVyPUOyMlM{OjVizszN NEnuN5FUSU6JRWK=
EB-3 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT3TWM2OD1|ND6zNVE4KM7:TR?= NWPubI15W0GQR1XS
HCC1187 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzXnBkUUN3ME2zOU45ODV{IN88US=> M4PDOHNCVkeHUh?=
SK-PN-DW MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDtTWM2OD1|Nj6xPVQ{KM7:TR?= M3jseXNCVkeHUh?=
JVM-3 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPxWVRHUUN3ME2zO{4zOzN6IN88US=> NYjJZXV7W0GQR1XS
HCC2157 NX7zfJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK0UpVKSzVyPUO3Mlk6PDZizszN NXX0ZWRbW0GQR1XS
A4-Fuk NYKxUXhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknWTWM2OD1|OD6xNFA6KM7:TR?= NX3NWWZkW0GQR1XS
COR-L279 NGjwS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7sZ3VKSzVyPUSwMlI5PTFizszN MWDTRW5ITVJ?
DEL Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDNTWM2OD12MT65NFg3KM7:TR?= NWPUPVZlW0GQR1XS
NCI-H1395 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR{LkCxOlMh|ryP Ml3UV2FPT0WU
MHH-NB-11 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfuWVJKSzVyPUSzMlA5OThizszN MYrTRW5ITVJ?
NCI-H2107 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3hTHdVUUN3ME20N{41QDR4IN88US=> MoDJV2FPT0WU
NEC8 M4XNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTR2LkOzOkDPxE1? NG\BOJRUSU6JRWK=
COLO-684 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ldmlEPTB;NE[uNlI2QCEQvF2= MV7TRW5ITVJ?
LS-411N M1;wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT0TWM2OD12OD60O|Q5KM7:TR?= NELnT3pUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
稳定性 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID